ATE366745T1 - Mutant er-alpha und nachweissysteme für transaktivierung - Google Patents

Mutant er-alpha und nachweissysteme für transaktivierung

Info

Publication number
ATE366745T1
ATE366745T1 AT00981647T AT00981647T ATE366745T1 AT E366745 T1 ATE366745 T1 AT E366745T1 AT 00981647 T AT00981647 T AT 00981647T AT 00981647 T AT00981647 T AT 00981647T AT E366745 T1 ATE366745 T1 AT E366745T1
Authority
AT
Austria
Prior art keywords
eralpha
mutant
test
transactivation
diagnosing
Prior art date
Application number
AT00981647T
Other languages
English (en)
Inventor
Koichi Saito
Norihisa Ohe
Hideo Satoh
Original Assignee
Sumitomo Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co filed Critical Sumitomo Chemical Co
Application granted granted Critical
Publication of ATE366745T1 publication Critical patent/ATE366745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mushroom Cultivation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00981647T 1999-12-07 2000-12-01 Mutant er-alpha und nachweissysteme für transaktivierung ATE366745T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP34802299 1999-12-07
JP37066799 1999-12-27
JP2000207011 2000-07-07
JP2000220508 2000-07-21
JP2000234053 2000-08-02
JP2000235461 2000-08-03
JP2000235463 2000-08-03
JP2000235460 2000-08-03

Publications (1)

Publication Number Publication Date
ATE366745T1 true ATE366745T1 (de) 2007-08-15

Family

ID=27573667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981647T ATE366745T1 (de) 1999-12-07 2000-12-01 Mutant er-alpha und nachweissysteme für transaktivierung

Country Status (8)

Country Link
US (1) US7582476B2 (de)
EP (1) EP1237925B1 (de)
JP (1) JP4742483B2 (de)
AT (1) ATE366745T1 (de)
AU (1) AU782142B2 (de)
CA (1) CA2393045A1 (de)
DE (1) DE60035522T2 (de)
WO (1) WO2001042307A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
EP1533368A4 (de) * 2002-07-02 2006-06-21 Astellas Pharma Inc Screening-verfahren für einen die insulinresistenz verbessernden arzneistoff
CA2957200C (en) 2002-10-16 2020-05-26 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
AU2003280793A1 (en) * 2002-11-15 2004-06-15 Sumitomo Chemical Company, Limited MUTANT ESTROGEN RECEPTOR-Alpha AND GENE THEREOF
WO2005040212A2 (en) * 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Orthogonal gene switches
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
EP1711606A2 (de) 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation der expression des glucocorticoidrezeptors
JP2006153656A (ja) * 2004-11-29 2006-06-15 Olympus Corp 反応カプセル、反応カプセルを使用した検査方法およびシステム
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
CN105451735B (zh) 2013-06-19 2019-01-11 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
US9855270B2 (en) * 2014-03-13 2018-01-02 Genentech, Inc. Methods and compositions for modulating estrogen receptor mutants
EP3303326B1 (de) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclische östrogen-rezeptormodulatoren und verwendungen davon
US10179676B1 (en) 2017-07-26 2019-01-15 William Hagan Taylor Dispenser with self-closing cap

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258401A4 (de) * 1986-02-20 1989-06-13 California Biotechnology Inc Eukaryotische expression von steroid-rezeptor-proteinen.
FR2634495B1 (fr) * 1988-07-01 1990-10-26 Chambon Pierre Procede de preparation d'une proteine par des levures utilisant un systeme inductible, vecteurs et souches transformees correspondantes
JPH06510363A (ja) * 1990-10-29 1994-11-17 ディカルブ　プラント　ジェネティクス 磁気性粒子を使用する生物学的材料の単離

Also Published As

Publication number Publication date
CA2393045A1 (en) 2001-06-14
DE60035522T2 (de) 2008-03-20
JP4742483B2 (ja) 2011-08-10
WO2001042307A1 (en) 2001-06-14
AU1886801A (en) 2001-06-18
DE60035522D1 (de) 2007-08-23
JP2003516137A (ja) 2003-05-13
EP1237925B1 (de) 2007-07-11
EP1237925A1 (de) 2002-09-11
AU782142B2 (en) 2005-07-07
US7582476B2 (en) 2009-09-01
US20030207380A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
ATE366745T1 (de) Mutant er-alpha und nachweissysteme für transaktivierung
WO2001042786A3 (en) System for cell based screening : cell spreading
Joensuu et al. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery
Speit et al. Investigations on the effect of cigarette smoking in the comet assay
Ladeira et al. Human biomonitoring: An overview on biomarkers and their application in occupational and environmental health
ES2160714T3 (es) Analisis y dispositivos para la deteccion de atresia biliar extrahepatica.
GB2383043A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain
PL325914A1 (en) Testing apparatus, application thereof, analysing system, method of making such apparatus and method of performing tests by means of such apparatus
Marshall et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
EP1260178A3 (de) Diagnose von Aufmerksamkeitsstörungen verbunden mit Hyperaktivität
GB2336684A (en) Predicting logarithmic reduction values
BRPI0410283A (pt) métodos de análise de uma região de ácido nucleico marcadora, de detecção ou monitoração de uma população clonal de células em um mamìfero, de diagnóstico e/ou de monitoração de uma condição de doença de mamìfero e de enriquecimento de uma população de moléculas de ácido nucleico em uma amostra biológica
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
IL147349A0 (en) Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
PT1171873E (pt) Aparelho e metodo para detectar emocoes na voz humana
RU2003106971A (ru) Способ оценки качества тестирующей полоски, устройство и считываемый компьютером носитель
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2004021008A3 (en) Methods for detecting breast and ovarian cancer
DE69528703T2 (de) VERFAHREN, REAGENZIEN UND TESTSATZ ZUR DIAGNOSE UND GEZIELTE SIEBTESTUNG FÜR p53 MÜTATIONEN
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
EP2177907A3 (de) Indikatormittel für nichtentzündliche Stressreaktion und Verwendung dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties